Company / Operating Income per Share
CytomX Therapeutics, Inc. Operating Income per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$0.16
FY2025
5-year range
-$1.77 / $0.31
FY2021-FY2025
Trend
-152.0%
vs FY2024
Sector context
#62 of 201
Health Care
What the data says
At $-0.16, CytomX Therapeutics, Inc.'s operating income per share ranks #62 of 201 in the Health Care sector. Operating Income per Share has fluctuated over the past 10 years, ranging from $-2.44 in FY2019 to $0.31 in FY2024.
Based on SEC 10-K filings.
-0.16 in FY2025.
Declined from $-0.10 to $-0.16 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#62 of 201 in Health CareTop 31% of 201This company -$0.16 Sector average -$28.56
▼
+99.4% above sector average
Key checks
Key Insights
- In FY2025, operating income per share decreased 152.0% year-over-year.
- Ranks #62 out of 201 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2024.
- Lowest operating income per share in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.16 | -152.0% |
| FY2024 | $0.31 | +423.9% |
| FY2023 | -$0.10 | +93.7% |
| FY2022 | -$1.53 | +13.8% |
| FY2021 | -$1.77 | -66.2% |
| FY2020 | -$1.07 | +56.2% |
| FY2019 | -$2.44 | -41.0% |
| FY2018 | -$1.73 | -43.7% |
| FY2017 | -$1.20 | +26.4% |
| FY2016 | -$1.63 | +89.1% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026